Bone Fragility-Contractures-Arterial Rupture-Hearing Loss Syndrome

Bone fragility-contractures-arterial rupture-hearing loss syndrome/BCARD syndrome is a very rare, inherited connective-tissue disease. “Connective tissue” is the body’s scaffolding—the collagen-rich material that gives strength and stretch to bone, ligaments, skin, blood vessels, eyes, and the inner ear. In this syndrome, a gene called PLOD3 does not work correctly. This gene makes an enzyme (lysyl hydroxylase-3, often called LH3) that helps collagen mature and function. When LH3 is faulty, collagen is built with the wrong chemical “finishing” and becomes weak or fragile. Because collagen is everywhere, many body parts are affected. Children and adults can have brittle bones (easy fractures and low bone density), joint contractures (joints stuck in bent or stiff positions), a risk of blood vessel tears or aneurysms (which can cause arterial rupture), eye problems (like high myopia or retinal detachment), and sensorineural hearing loss. The condition is autosomal recessive—a person is affected when they inherit one faulty copy of the gene from each parent. Genome.jp+3PMC+3NCBI+3

BCARD is a very rare inherited connective-tissue disorder caused by harmful changes in the PLOD3 gene, which makes the enzyme lysyl-hydroxylase-3 (LH3). LH3 helps collagen molecules form stable, strong links. When LH3 does not work well, collagen in many body tissues is weaker. This can lead to fragile bones (easy fractures and low bone density), joint contractures (stiff joints at birth or early life), risk of blood vessel aneurysm and rupture, eye problems, and sensorineural hearing loss. Because many organs use collagen, care must be team-based and lifelong. (Sources: MedGen/NCBI, Orphanet, GARD, Monarch Initiative, MalaCards). malacards.org+4NCBI+4Orpha.net+4

Why bones, joints, arteries, eyes, and ears are affected. Collagen needs specific chemical “finishing steps” to become strong. LH3 adds hydroxyl and sugar groups to collagen lysine residues—key for cross-linking and basement-membrane stability. With LH3 deficiency, collagen networks in bone (type I), vessel walls (types III/IV), and inner ear/ocular tissues are less stable, explaining fractures, contractures, aneurysm risk, and hearing loss. (Sources: MedGen summary of phenotype and collagen biology linked to PLOD3/LH3). NCBI

---

Other names

Doctors, labs, and databases may use several names that all refer to the same disorder:

• BCARD syndrome (Bone fragility with Contractures, Arterial Rupture, and Deafness)

• Lysyl hydroxylase-3 deficiency / LH3 deficiency

• Connective tissue disorder due to lysyl hydroxylase-3 deficiency

• Bone fragility-contractures-arterial rupture-deafness syndrome

• MONDO:0012892; OMIM #612394 (catalog identifiers used by genetics databases)
  These names all point to disease caused by biallelic (two-copy) pathogenic variants in PLOD3. PubMed+3Orpha.net+3malacards.org+3

---

Types

There is no official set of clinical “types” like Type 1, 2, 3, etc., for BCARD. But doctors often describe it in useful sub-patterns to guide care:

1. Classic BCARD phenotype: bone fragility, multiple joint contractures, hearing loss, eye disease, and risk of arterial aneurysm/dissection. NCBI

2. Vascular-predominant phenotype: similar skeletal and eye/ear features, but with more severe blood vessel problems (popliteal, cerebral, or other arterial aneurysm; risk of rupture). malacards.org

3. Oculo-skeletal (“Stickler-like”) phenotype: strong eye involvement (high myopia, vitreous anomalies, retinal detachment) with bone fragility/contractures and variable hearing loss. ResearchGate

4. Severity spectrum by mutation function: variants that mainly damage LH3’s hydroxylase activity versus variants that also impair its glycosyltransferase steps may influence which organs are most affected and how severe the disease is. PMC

---

Causes

Remember: the root cause is pathogenic variants in the PLOD3 gene. The list below breaks that down into plain-language “causes and contributors” that explain why the body shows these features:

1. Biallelic PLOD3 variants (inherited from both parents) directly cause BCARD. NCBI

2. Loss of LH3 enzyme function—collagen is not modified correctly. PMC

3. Defective lysine hydroxylation in collagen chains weakens the collagen scaffold. PMC

4. Abnormal glycosylation of hydroxylysine residues further disrupts collagen stability. PMC

5. Weak bone matrix develops, lowering bone mineral density and raising fracture risk. NCBI

6. Stiff/shortened connective tissues around joints cause contractures. NCBI

7. Fragile arterial walls (poor collagen/elastin network) promote aneurysm and dissection. Genome.jp

8. Inner-ear (cochlear) collagen defects cause sensorineural hearing loss. NCBI

9. Vitreous and retinal collagen defects lead to high myopia and retinal detachment risk. NCBI

10. Skin and nail changes (easy bruising, blistering, hypoplastic nails) reflect global collagen weakness. BioMed Central

11. Facial connective tissue differences contribute to characteristic facial features (dysmorphism). BioMed Central

12. Growth restriction (before and after birth) can occur due to systemic collagen dysfunction. malacards.org

13. Compound heterozygosity (two different PLOD3 variants) can produce disease. IOSR Journals

14. Missense / nonsense / frameshift / splice variants in PLOD3 have all been reported. PMC

15. Founder effects or consanguinity may raise risk in some families/populations. (General genetic principle noted in rare autosomal-recessive disorders.) NCBI

16. Basement membrane defects (collagen IV processing) may add eye/ear/skin fragility. PMC

17. Small-vessel brain involvement can stem from abnormal vascular collagen. Wiley Online Library

18. Diaphragm/connective tissue fragility may occur (reported in LH3 deficiency case summaries). malacards.org

19. Whole-body collagen network failure explains why many organs are affected at once. PMC

20. Autosomal-recessive inheritance explains why unaffected parents can have affected children. NCBI

---

Symptoms and signs

1. Bone fragility and frequent fractures—bones break more easily, even with mild trauma. NCBI

2. Low bone mineral density (osteopenia/osteoporosis)—thin, weak bones on scans. NCBI

3. Joint contractures—elbows, knees, fingers, or feet are stiff or stuck in bent positions. NCBI

4. Scoliosis—spine curves because supporting tissues are weak. BioMed Central

5. Prominent knees or limb deformities—abnormal limb alignment from soft-tissue and bone weakness. NCBI

6. Sensorineural hearing loss—hearing nerve/inner ear damage due to faulty collagen. NCBI

7. High myopia (severe near-sightedness)—eye’s structure is altered, stretching occurs. NCBI

8. Vitreous abnormalities and retinal detachment risk—the eye’s gel and retina can be fragile. NCBI

9. Arterial aneurysm or dissection—ballooning or tearing of arteries; can be life-threatening. Genome.jp

10. Easy bruising / soft, fragile skin—reduced tissue strength leads to bruises or blisters. BioMed Central

11. Hypoplastic nails / hair differences—nails may be under-developed; hair may be coarse/abnormal. BioMed Central

12. Growth delay—short stature or low weight compared with peers. malacards.org

13. Facial features—subtle dysmorphism may be noted by clinicians familiar with the syndrome. malacards.org

14. Muscle weakness and joint laxity in some areas—paradox of stiff contractures with lax other joints. BioMed Central

15. Neurologic events from vascular problems—if brain vessels are involved (rare), symptoms like headache, stroke-like events, or seizures can occur. Wiley Online Library

---

Diagnostic tests

A) Physical examination

1. Whole-body musculoskeletal exam: checks spine curve, limb alignment, joint range, and signs of fractures or deformities. Findings guide early bracing, therapy, and fracture prevention. BioMed Central

2. Skin, hair, and nails exam: looks for easy bruising, blistering, soft or fragile skin, sparse palmar creases, or hypoplastic nails—clues to systemic collagen disease. BioMed Central

3. Cardiovascular exam: blood pressure in arms/legs, pulse quality, and any new murmurs; sudden pain, neurologic changes, or pulse differences can suggest arterial dissection or aneurysm. Genome.jp

4. ENT/hearing screen: bedside voice or tuning-fork checks can flag hearing loss for formal testing. NCBI

5. Ophthalmic screen (basic): bedside visual acuity and red-reflex check to catch severe myopia or retinal issues early; prompts urgent referral to ophthalmology. NCBI

B) Manual / bedside functional tests

6. Range-of-motion (ROM) goniometry: measures joint angles to document contractures and track therapy response. BioMed Central

7. Functional mobility tests (e.g., timed up-and-go, gait observation): simple measures of balance and movement that guide physical therapy. BioMed Central

8. Postural assessment for scoliosis (Adams forward-bend with scoliometer): low-tech screen for spinal curvature needing imaging. BioMed Central

C) Laboratory and pathological tests

9. Genetic testing for PLOD3 (single-gene or panel; confirm with exome/genome if needed): detects biallelic pathogenic variants and confirms the diagnosis. Parental testing defines carrier status. NCBI

10. Collagen post-translational analysis (specialized research labs): assesses collagen hydroxylation/glycosylation patterns that support LH3 deficiency when genetics is unclear. PMC

11. Bone turnover markers (alkaline phosphatase, P1NP, CTX): help monitor bone formation/resorption and response to therapy (e.g., bisphosphonates under specialist care). (General bone-health practice applied to this genetic disorder.) NCBI

12. Basic metabolic panel, calcium, phosphate, vitamin D: rule out additional correctable contributors to low bone density. (Supportive in any fragility syndrome.) NCBI

13. Urinalysis / renal panel if on bone-active drugs: safety monitoring when treatments are used. (General safety practice.) NCBI

14. Skin biopsy (selected cases): can show basement membrane/collagen abnormalities; used mainly in research or when diagnosis remains uncertain. PMC

D) Electrodiagnostic / sensory tests

15. Pure-tone audiometry: formal hearing test to quantify sensorineural loss and plan hearing aids or other support. NCBI

16. Otoacoustic emissions / auditory brainstem response (ABR): useful in infants or when standard audiometry is not possible. NCBI

17. Electroretinography / visual electrophysiology (specialist): eye-electrical tests when retinal disease is suspected or surgery is planned. NCBI

E) Imaging tests

18. Dual-energy X-ray absorptiometry (DXA): measures bone mineral density and tracks fragility over time. NCBI

19. Whole-spine and limb radiographs: assess fractures, deformities, and scoliosis progression; helps decide on bracing or orthopedics. BioMed Central

20. Arterial imaging (echocardiography for aortic root, CT/MR angiography of cerebral and peripheral vessels): screens for aneurysm or dissection given known risk; essential after suggestive symptoms or at baseline in specialized centers. Genome.jp

Non-pharmacological treatments

1) Lifelong multidisciplinary care program.
Description: Build a stable team (clinical genetics, orthopedics, physiatry/physiotherapy, cardiology/vascular surgery, neurosurgery as needed, ophthalmology, audiology, pain medicine, dentistry, psychology). Schedule regular surveillance for bones, vessels, eyes, and hearing. Educate family on safe handling, fall prevention, and emergency signs of arterial events. Purpose: Coordinate prevention, early detection, and timely interventions. Mechanism: Team-based monitoring catches complications early and tunes care plans to growth and life stages. (Rare-disease overviews emphasize multi-system surveillance in LH3 deficiency). NCBI+1

2) Individualized physiotherapy (low-impact, contracture-focused).
Description: Daily gentle range-of-motion, stretching, splinting where needed, progressive muscle strengthening without high-impact loads, aquatic therapy, and posture training. Purpose: Reduce contracture progression, maintain function, and lower fracture risk by improving balance and protective reflexes. Mechanism: Gradual musculoskeletal conditioning increases joint range and neuromuscular control without stressing fragile bone. (Physio guidance for arthrogryposis/contractures adapted to bone fragility). Physiopedia

3) Safe-movement and fracture-prevention coaching.
Description: Teach transfer techniques, use of gait aids, protective home setup (grab bars, non-slip floors, cushioned corners). Purpose: Minimize falls and torsion forces. Mechanism: Environmental and behavioral modifications reduce mechanical energy transferred to brittle bones. (Bone-fragility content from OI care extrapolated for safety strategies). PMC

4) Orthotic management and custom bracing.
Description: Night splints, dynamic orthoses, ankle-foot orthoses, and spinal bracing for scoliosis as indicated. Purpose: Maintain limb alignment, reduce contracture stress, and support ambulation. Mechanism: External stabilization redistributes loads across joints and bone, lowering microfracture risk. (Contracture/arthrogryposis orthotic principles). Physiopedia

5) Fall-proof home and school plan.
Description: Lighting, assistive rails, ramps, seated showering, proper footwear, supervised PE with low-impact sports (swimming, cycling with protections). Purpose: Prevent fractures. Mechanism: Reduces slip and impact exposure. (General bone-fragility prevention practices). PMC

6) Aneurysm/artery surveillance protocol.
Description: Baseline and periodic imaging (echocardiography, MR/CT angiography) of aorta and major branches; more frequent scans if dilation is detected. Emergency education for sudden chest/abdominal/back pain. Purpose: Detect aneurysms/dissections early; guide timing of vascular repair. Mechanism: Surveillance tracks diameter and growth rates to apply guideline thresholds. (ACC/AHA aortic disease guidance; ESVS surveillance principles). AHA Journals+2NCBI+2

7) Blood-pressure optimization (lifestyle).
Description: Low-salt diet, weight management, sleep hygiene, stress reduction, and regular low-intensity aerobic activity. Purpose: Lower hemodynamic stress on fragile arteries. Mechanism: BP reduction reduces wall tension (Laplace’s law) and rupture risk. (Aortic disease care emphasizes BP control). AHA Journals

8) Hearing rehabilitation (audiology, hearing aids, cochlear implant as needed).
Description: Early audiology testing; fit hearing aids; consider cochlear implant for severe loss; speech therapy for language milestones. Purpose: Preserve communication and development. Mechanism: Amplification or neural stimulation compensates for sensorineural deficits. (Disease summaries note sensorineural deafness). NCBI

9) Ophthalmic surveillance and protection.
Description: Annual dilated eye exams for myopia, lens changes, retinal risks; protective eyewear; prompt care for flashes/floaters. Purpose: Prevent vision loss from retinal detachment or cataract. Mechanism: Early detection + protective measures reduce traction and impact injuries. (Phenotype includes high myopia/cataract/retinal risk). NCBI

10) Dental and jaw care.
Description: Regular dental visits, soft toothbrushes, fluoride, and periodontal care; pre-procedure planning if on antiresorptives to limit osteonecrosis of jaw risk. Purpose: Maintain oral health and lower procedure complications. Mechanism: Good oral hygiene reduces invasive procedures; planning mitigates antiresorptive-related risks. (ONJ precautions from denosumab/bisphosphonate labels). FDA Access Data+1

11) Pain management plan (non-opioid first).
Description: Use acetaminophen/NSAIDs for mild-moderate pain, regional blocks for peri-operative pain; cognitive-behavioral strategies. Purpose: Control pain yet avoid sedation and falls. Mechanism: Multimodal analgesia lowers pain signals while minimizing fracture-risking side effects. (General bone-fragility pain care; ibuprofen/acetaminophen supportive). PMC

12) Nutrition with bone and vascular focus.
Description: Adequate calcium, vitamin D, protein, fruits/vegetables; limit ultra-processed foods and excess salt; ensure hydration. Purpose: Support bone remodeling and BP control. Mechanism: Nutrient sufficiency supports collagen/bone matrix and endothelial health; salt reduction aids BP. (OI nutrition principles extrapolated + BP dietary guidance). PMC+1

13) Safe exercise prescription.
Description: Supervised aquatic therapy, stationary cycling, light resistance bands; avoid contact/high-impact sports. Purpose: Improve muscle-bone unit and balance safely. Mechanism: Low-impact loading improves bone health without fracture-level forces. (Pediatric bone-fragility rehabilitation experience). PMC

14) School/occupation accommodations.
Description: Individual Education Plan, elevator access, lighter backpacks, ergonomic seating, flexible schedules. Purpose: Maintain participation while minimizing risk. Mechanism: Reduces physical strain and fall hazards. (General rare-disease functional care). Genetic & Rare Diseases Info Center

15) Fracture-care protocols with gentle handling.
Description: Low-force casting, careful positioning, early mobilization when safe; document prior fractures/surgeries. Purpose: Heal fractures while preventing new ones. Mechanism: Minimizes iatrogenic stress on fragile bones. (OI/Bruck fracture-care experience adapted). PMC+1

16) Scoliosis monitoring and early orthopedics input.
Description: Standing spine films on schedule; brace trials; surgical referral if curves progress. Purpose: Protect lung function and mobility. Mechanism: Early detection enables conservative measures before structural deformity stabilizes. (Phenotype includes scoliosis). cags.org.ae

17) Pregnancy and family-planning counseling.
Description: Pre-conception counseling, high-risk obstetric care, vascular screening before/during pregnancy. Purpose: Reduce maternal arterial events and plan safe delivery. Mechanism: Anticipatory risk assessment in hemodynamic stress states. (Aortic disease guideline principles applied to heritable CTD). AHA Journals

18) Genetic counseling and cascade testing.
Description: Explain autosomal-recessive inheritance; offer partner testing, prenatal options, or preimplantation genetic testing where legal and desired. Purpose: Informed choices for families. Mechanism: Identification of PLOD3 variants clarifies recurrence risk. (GARD/MedGen entries). Genetic & Rare Diseases Info Center+1

19) Emergency plan and medical alert.
Description: Wallet card/bracelet listing condition, imaging needs, and “suspect arterial event with sudden pain.” Purpose: Speed triage. Mechanism: Rapid recognition triggers appropriate imaging and vascular consult. (Aortic emergency best practices). AHA Journals

20) Mental-health and social support.
Description: Counseling, peer support, fatigue management, caregiver training. Purpose: Reduce anxiety/depression and improve adherence. Mechanism: Psychosocial care strengthens coping skills and self-management. (Rare-disease care frameworks). Genetic & Rare Diseases Info Center

---

Drug treatments

Important: No medicine “fixes” LH3. Drug therapy here is supportive or risk-reducing and often off-label in BCARD. Bone-active agents (bisphosphonates, denosumab, teriparatide) have evidence in osteoporosis/OI; use requires specialist oversight and label precautions. Doses below quote FDA labels for their approved uses (not specific to BCARD) so clinicians can cross-check safety.

1) Zoledronic acid (Reclast®/Zometa®) — bisphosphonate.
Description (150 words): Potent IV antiresorptive that binds bone mineral and inhibits osteoclasts. Used yearly (5 mg) in osteoporosis, and cyclically in children with OI (off-label) to improve bone mineral density and reduce vertebral compression. In BCARD, specialists sometimes extrapolate from OI for severe low BMD or recurrent fractures. Monitor kidney function; infuse over ≥15 minutes; consider acetaminophen after infusion to lessen flu-like reactions. Dental evaluation before therapy helps reduce osteonecrosis-of-jaw risk. Class: Bisphosphonate. Dosage/Time (per osteoporosis label): 5 mg IV once yearly (Reclast). Purpose: Increase bone density; possibly lower fracture risk. Mechanism: Inhibits farnesyl pyrophosphate synthase in osteoclasts, reducing bone resorption. Side effects: Acute-phase symptoms, hypocalcemia, renal impairment, ONJ, atypical femur fracture (rare). (FDA label + OI evidence). FDA Access Data+2FDA Access Data+2

2) Pamidronate (Aredia®) — bisphosphonate.
Description: Widely used in pediatric OI (off-label) in cyclical IV courses; may be considered in BCARD for severe fragility under expert care. Renal monitoring and slow infusion are essential. Class: Bisphosphonate. Dosage/Time (label varies by approved oncology uses; OI cycles are off-label): See label for infusion preparation; pediatric OI regimens are not on the label. Purpose: Improve vertebral BMD and reduce bone pain. Mechanism: Osteoclast inhibition. Side effects: Flu-like symptoms, hypocalcemia, renal effects, ONJ (rare). (FDA label + OI reviews). FDA Access Data+2FDA Access Data+2

3) Teriparatide (Forteo®) — PTH(1-34) anabolic.
Description: Intermittent PTH analog that stimulates osteoblasts more than osteoclasts, increasing bone formation. Approved for high-risk osteoporosis in adults; not for growing children. In BCARD adults with severe low BMD or fractures despite antiresorptives, specialists may consider it (watch cumulative duration). Class: Anabolic osteoporosis therapy. Dosage/Time (label): 20 mcg SC once daily; lifetime duration limits per current label. Purpose: Build trabecular bone and improve microarchitecture. Mechanism: Activates PTH receptors to favor bone formation. Side effects: Hypercalcemia, dizziness, leg cramps; box warnings evolved—check current label. (FDA label). FDA Access Data

4) Denosumab (Prolia®) — RANKL inhibitor.
Description: Monoclonal antibody that blocks RANKL, suppressing osteoclasts. Given every 6 months for osteoporosis in adults with high fracture risk; discontinuation requires transition plan to avoid rebound vertebral fractures. In BCARD adults, useful when bisphosphonates are contraindicated (e.g., renal impairment). Class: Antiresorptive. Dosage/Time (label): 60 mg SC every 6 months. Purpose: Increase BMD and reduce fractures. Mechanism: RANKL neutralization prevents osteoclast formation and survival. Side effects: Severe hypocalcemia (especially CKD), infections, dermatitis/eczema, ONJ, atypical femur fracture; boxed warning for advanced CKD. (FDA label, 2024-25 updates). FDA Access Data+1

5) Calcium (elemental) — medical nutrition therapy.
Description: Ensures substrate for bone mineralization when using antiresorptives/anabolics. Dose individualized to diet and labs; avoid excess. Class: Supplement (not a drug in Rx sense). Dosage/Time: Commonly 1000–1200 mg/day total intake in adults (diet+supplement) per general bone health guidance; pediatric dosing individualized. Purpose: Support bone treatments, reduce hypocalcemia risk. Mechanism: Provides Ca²⁺ for hydroxyapatite and neuromuscular function. Side effects: Constipation, kidney stones with excess. (Given alongside antiresorptives per labels). FDA Access Data+1

6) Vitamin D (cholecalciferol/ergocalciferol).
Description: Correct deficiency and maintain sufficiency to enable calcium absorption and antiresorptive safety. Class: Vitamin therapy. Dosage/Time: Per guidelines and level monitoring. Purpose: Prevent hypocalcemia and support bone remodeling. Mechanism: Increases intestinal calcium uptake and bone mineralization. Side effects: Hypercalcemia with overdose. (Co-administration emphasized in osteoporosis labels). FDA Access Data

7) Acetaminophen — analgesic/antipyretic.
Description: First-line for fracture or postoperative pain when NSAIDs are not ideal. Class: Non-opioid analgesic. Dosage/Time: Per over-the-counter labeling and clinician guidance. Purpose: Pain control without platelet or renal effects of NSAIDs. Mechanism: Central COX modulation. Side effects: Hepatotoxicity with overdose. (General analgesic role; also mentioned in zoledronic acid label for post-infusion symptoms). FDA Access Data

8) Ibuprofen — NSAID.
Description: Useful for short-term pain and post-infusion symptoms after zoledronic acid. Class: NSAID. Dosage/Time: Per OTC/prescription guidance. Purpose: Reduce inflammatory pain. Mechanism: COX inhibition. Side effects: GI irritation/bleeding, renal effects. (Reclast label note on ibuprofen use for acute-phase reactions). FDA Access Data

9) Losartan (Cozaar®) — ARB for BP control.
Description: Tight BP control reduces wall stress in at-risk arteries. While losartan is not specific to BCARD, ARBs are standard antihypertensives and are used widely in heritable aortopathies to manage afterload. Class: Angiotensin II receptor blocker. Dosage/Time (label, adults): Common starting 50 mg daily; adjust to response. Purpose: Lower BP; potentially reduce arterial dilation rate per broader aortopathy practice. Mechanism: AT1 receptor blockade reduces vasoconstriction and aldosterone effects. Side effects: Hyperkalemia, hypotension, rare angioedema; pregnancy contraindicated. (FDA label; aortic guidelines emphasize BP control). FDA Access Data+1

10) Metoprolol succinate (Toprol-XL®) — beta-blocker for BP/HR control.
Description: Lowers heart rate and systolic pressure, reducing pulsatile aortic wall stress; standard tool in aortopathy care plans (not BCARD-specific). Class: β1-selective blocker. Dosage/Time (label): Titrate (e.g., 25–200 mg once daily) to BP/HR goals per label. Purpose: Hemodynamic moderation for aneurysm risk reduction strategy. Mechanism: β1 blockade lowers inotropy/chronotropy. Side effects: Bradycardia, fatigue, dizziness; taper to avoid rebound. (FDA label; aortic guideline rationale). FDA Access Data+1

11) Peri-operative tranexamic acid (select cases).
Description: Antifibrinolytic sometimes used during major orthopedic or vascular procedures to reduce bleeding (surgeon-led decision). Class: Antifibrinolytic. Dosage/Time: Procedure-specific. Purpose: Lower transfusion risk. Mechanism: Blocks plasminogen activation. Side effects: Thrombosis risk; use with caution. (General surgical hemostasis practice). JVASCSurg

12) Antibiotic prophylaxis per procedure risk.
Description: For certain surgeries or invasive dental work, follow standard prophylaxis rules (not disease-specific). Class: Antimicrobials. Dosage/Time: Per procedural guidelines. Purpose: Prevent infection that might jeopardize bone hardware or vascular grafts. Mechanism: Pre-emptive bacterial suppression. (General perioperative standards). JVASCSurg

13) Topical fluoride therapy (dental).
Description: Strengthen enamel in patients at risk of dental issues and to minimize invasive procedures if on antiresorptives. Class: Topical dental agent. Dosage/Time: Dentist-guided. Purpose: Reduce caries and future invasive work. Mechanism: Improves enamel remineralization. Side effects: Minimal with topical use. (ONJ warnings prompt dental prevention). FDA Access Data

14) Peri-infusion acetaminophen/NSAID (zoledronic acid).
Description: To reduce acute-phase reaction symptoms after first infusion. Class: Analgesics/antipyretics. Dosage/Time: Single-day dosing around infusion per label advice. Purpose: Comfort and adherence. Mechanism: Prostaglandin modulation. Side effects: As above. (Reclast label). FDA Access Data

15) Calcium/vitamin D repletion before antiresorptive therapy.
Description: Corrects deficiency to avoid hypocalcemia and supports bone mineralization. Class: Supplement therapy. Dosage/Time: Based on labs. Purpose: Safety and efficacy of antiresorptives/denosumab. Mechanism: Ensures positive calcium balance. Side effects: Hypercalcemia if excessive. (Prolia/Reclast labels). FDA Access Data+1

16) Post-denosumab transition therapy (e.g., short bisphosphonate course).
Description: If denosumab is stopped, give a plan to prevent rebound bone loss. Class: Sequential antiresorptive. Dosage/Time: Specialist-determined. Purpose: Avoid rebound vertebral fractures. Mechanism: Consolidates gains while RANKL inhibition wanes. Side effects: As per agent. (Prolia label warnings). FDA Access Data

17) Peri-fracture DVT prophylaxis (when immobilized).
Description: Anticoagulants during immobilization periods as indicated. Class: Antithrombotic. Dosage/Time: Protocol-based. Purpose: Prevent clots during casting/surgery. Mechanism: Coagulation pathway modulation. Side effects: Bleeding. (General ortho standards). JVASCSurg

18) Ophthalmic drops (as indicated for co-existing issues).
Description: Treat ocular hypertension, inflammation, or post-op needs per ophthalmology. Class: Various. Dosage/Time: Eye-specific. Purpose: Preserve vision. Mechanism/Side effects: Per drug class. (Ocular involvement noted in phenotype). NCBI

19) Vaccinations (standard schedule).
Description: Keep immunizations up to date; consider extra infection-prevention strategies around surgeries. Class: Preventive biologics. Dosage/Time: Per national schedules. Purpose: Reduce infection-triggered setbacks. Mechanism: Active immunity. Side effects: Typical vaccine reactions. (General preventive care for medically fragile patients). Genetic & Rare Diseases Info Center

20) Individualized anesthesia plan (medication choices).
Description: Avoid excessive neck manipulation if cervical instability; cautious BP management to limit arterial stress; regional techniques when safe. Class: Anesthesia pharmacology. Dosage/Time: Case-specific. Purpose: Reduce peri-operative complications. Mechanism: Tailored hemodynamics and positioning. Side effects: Anesthetic class-specific. (Aortic and connective-tissue peri-op principles). AHA Journals

---

Dietary molecular supplements

1) Vitamin D3 (cholecalciferol). Supports calcium absorption and bone mineralization; crucial with antiresorptives to prevent hypocalcemia. Dose guided by 25-OH vitamin D levels; avoid overdosing. Mechanism: Nuclear VDR activation in gut increases calcium uptake; synergy with calcium for hydroxyapatite. Evidence basis comes from its standard co-therapy role in osteoporosis and in labels for antiresorptives. FDA Access Data+1

2) Calcium citrate/carbonate. Provides elemental calcium to reach age-appropriate totals when diet is insufficient; citrate option suits low stomach acid. Mechanism: Supplies Ca²⁺ for mineralization and neuromuscular stability; needed with potent antiresorptives. Monitor total intake to avoid stones. FDA Access Data

3) Protein (whey/casein) supplementation when dietary intake is low. Adequate protein supports collagen synthesis and fracture healing; dose individualized (e.g., 1.0–1.2 g/kg/day adults if safe). Mechanism: Provides amino acids (glycine, proline, lysine) for collagen triple helix. PMC

4) Magnesium (deficiency correction). Low Mg impairs PTH secretion and vitamin D activation; repletion supports bone turnover balance. Mechanism: Cofactor in enzymatic steps for bone matrix mineralization. Use lab-guided dosing to avoid diarrhea or hypermagnesemia. PMC

5) Vitamin K (K1/K2) — cautious, clinician-guided. Supports γ-carboxylation of osteocalcin; consider only if no anticoagulant conflicts. Mechanism: Enables osteocalcin binding to bone mineral, aiding micro-architecture. Evidence mixed; avoid in patients on warfarin. PMC

6) Omega-3 fatty acids (EPA/DHA). May support vascular health and lower inflammation; not a direct BCARD therapy, but potentially helpful for cardiometabolic risk. Mechanism: Membrane and eicosanoid effects that can modestly lower BP and inflammation. Avoid excess around surgeries. AHA Journals

7) Collagen peptides (adjunct). Provide amino acid building blocks; limited evidence for BMD, but safe adjunct to optimize protein quality if diet is poor. Mechanism: Supplies glycine/proline/hydroxyproline substrates. Use as nutrition support, not as treatment. PMC

8) Citrate salts (potassium citrate) when indicated. For patients with low urinary citrate or stone risk, citrate can reduce calcium stone formation and may create a mild alkali load favorable to bone. Mechanism: Binds urinary calcium, reduces bone buffering of acid. Only if clinically indicated. PMC

9) Antioxidant-rich food concentrates (e.g., berry polyphenols). Emphasize food-first: fruits/vegetables support endothelial function and general health; supplements only if diet is limited. Mechanism: Nitric-oxide bioavailability and anti-oxidative pathways support vascular tone. AHA Journals

10) Probiotics (selected strains). Early data link gut microbiota to mineral absorption and inflammation; use food sources (yogurt) preferentially. Mechanism: SCFA production may aid mineral uptake and immune balance. Evidence evolving; use under clinician advice. PMC

---

Immunity-booster / Regenerative / Stem-cell” drugs

There is no approved regenerative or stem-cell drug for BCARD. Items below reflect general bone/immune support concepts used clinically in other contexts; in BCARD, they are experimental/off-label and require specialist and ethics oversight.

1) Teriparatide (see above). Anabolic osteoanabolic used in adults to stimulate new bone formation; not for children. Mechanism: Intermittent PTH receptor activation increases osteoblast activity. Dose: 20 mcg SC daily (label). Function: Build trabecular bone where fractures cluster. Caution: Hypercalcemia; duration limits. FDA Access Data

2) Abaloparatide. Another PTHR agonist for high-risk postmenopausal osteoporosis; off-label if ever considered. Mechanism: Osteoblast stimulation. Dose: Per label in approved populations. Function: Increase BMD; transition plan needed. Caution: Hypercalcemia, orthostatic dizziness. (General osteoporosis pharmacology; label cross-check required). PMC

3) Romosozumab. Sclerostin inhibitor with dual anabolic/antiresorptive effect for severe osteoporosis in specific adults; carries cardiovascular warnings. Mechanism: Promotes Wnt signaling in osteoblasts. Dose: Monthly SC injections for 12 months (label). Function: Rapid BMD gains. Caution: Avoid with recent MI/stroke; not pediatric. (Osteoporosis labels/guidance). PMC

4) Denosumab transition strategy. After 12+ months of denosumab, a single IV zoledronic acid dose sometimes used to lock in gains if stopping; off-label strategy guided by specialist. Function: Prevent rebound bone turnover. Mechanism: Sequential antiresorptive effect. Caution: Hypocalcemia; ONJ risks persist. (Prolia label warnings on discontinuation). FDA Access Data

5) Hematopoietic growth factors (only if indicated). Not for BCARD per se; used only when separate blood count problems exist. Mechanism: Stimulate marrow lineages. Function: Treat comorbid cytopenias, not BCARD itself. Caution: Indication-restricted. (General hematology practice). PMC

6) Investigational cell-based bone repair (research setting only). Selected centers study MSC-assisted grafting for non-unions in other disorders; not standard for BCARD. Mechanism: Osteogenic support via paracrine signaling and scaffold seeding. Function: Experimental repair of complex defects. Caution: Research protocols only. (General ortho-regenerative literature). PMC

---

Surgeries (what they are; why done)

1) Fracture fixation with gentle, low-stress techniques.
Why: Stabilize displaced fractures to allow healing and regain function. Procedure: Low-profile plates/rods, careful positioning, avoid excessive torque; early mobilization when safe. (Ortho care extrapolated from OI/Bruck). PMC

2) Corrective osteotomies and guided growth.
Why: Realign deformities that impair gait or cause pain. Procedure: Planned cuts and fixation; sometimes growth-modulation plates in children; prolonged rehab. PMC

3) Spinal fusion for progressive scoliosis.
Why: Prevent cardiopulmonary compromise and progressive deformity. Procedure: Instrumented fusion with meticulous blood conservation and neuromonitoring. cags.org.ae

4) Elective vascular repair (open or endovascular).
Why: Treat enlarging aneurysm or dissection to prevent rupture. Procedure: Graft replacement or endovascular stent-graft; follow strict size/growth criteria and surveillance. AHA Journals+1

5) Cochlear implantation (selected cases).
Why: Severe sensorineural hearing loss not corrected by hearing aids. Procedure: Surgical placement of electrode array; extensive audiology rehabilitation. NCBI

---

Preventions

1. Keep BP in target range with lifestyle and, if needed, medicines to reduce arterial stress. AHA Journals

2. Stick to a scheduled vascular imaging plan to catch aneurysms early. AHA Journals

3. Practice home fall-prevention and safe transfer methods daily. PMC

4. Use low-impact exercise with supervision to build strength and balance. PMC

5. Maintain adequate calcium, vitamin D, and protein intake; avoid excess salt. FDA Access Data

6. Wear protective eyewear and seek urgent care for retinal warning signs. NCBI

7. Keep dental hygiene excellent—especially before/while on antiresorptives. FDA Access Data

8. Schedule routine hearing checks; use hearing aids early if needed. NCBI

9. Plan pregnancies with high-risk obstetric/vascular teams. AHA Journals

10. Carry an emergency card/medical alert about arterial-rupture risk. AHA Journals

---

When to see doctors

• Immediately (ER): Sudden severe chest, abdomen, back, or neck pain; fainting; stroke signs; acute limb pain/pallor—possible arterial dissection/rupture. Start emergency imaging. AHA Journals

• Urgent clinic: New hearing drop, flashes/floaters or curtain-like vision change, painful swollen limb after minor trauma, rapid spine curve change, uncontrolled pain. NCBI

• Routine: Scheduled bone density checks, vascular imaging, yearly eye/hearing exams, dental cleanings, physiotherapy reviews, and medication monitoring labs. NCBI+1

---

What to eat and what to avoid

1. Eat lean proteins (fish, eggs, dairy/fortified alternatives, legumes) to support collagen repair. Avoid very low-protein diets. PMC

2. Eat calcium-rich foods (dairy/fortified plant milks, leafy greens). Avoid chronic calcium deficiency or excessive supplements without labs. FDA Access Data

3. Eat vitamin-D sources and safe sun exposure; supplement only as directed. Avoid megadoses without testing. FDA Access Data

4. Eat fruits/vegetables daily for vascular health. Avoid ultra-processed high-salt snacks; salt raises BP. AHA Journals

5. Drink adequate water. Avoid dehydration that can worsen dizziness/fall risk. PMC

6. Consider omega-3-rich fish weekly. Avoid starting capsules close to major surgery unless cleared. AHA Journals

7. Use fortified cereals for vitamin K/B nutrients unless on warfarin. Avoid supplement-drug conflicts. PMC

8. Time calcium away from certain medications (iron, some antibiotics) to prevent interactions. FDA Access Data

9. Limit alcohol; it worsens falls and bone loss. PMC

10. Keep weight in a healthy range to reduce joint load and BP. AHA Journals

---

Frequently asked questions

1) Is there a cure?
No. Care focuses on strengthening bones, preventing fractures, monitoring and treating aneurysms, protecting vision/hearing, and supporting daily function. Genetic counseling helps families plan. (Disease overviews). NCBI+1

2) Is it always inherited?
Usually autosomal-recessive due to PLOD3 variants; some families have two carrier parents. A geneticist can confirm and advise relatives. NCBI

3) How is it diagnosed?
By the clinical pattern plus genetic testing showing PLOD3 variants; imaging evaluates bone density and blood vessels; eye and hearing tests look for complications. NCBI

4) What is the biggest immediate danger?
Unrecognized arterial aneurysm/dissection/rupture. This is why BP control and scheduled imaging are essential. AHA Journals

5) Can bone medicines help?
Yes—in selected patients, bone-active drugs used for osteoporosis/OI (bisphosphonates, denosumab, teriparatide) may improve BMD and reduce fracture risk; this is specialist-guided and often off-label in BCARD. FDA Access Data+1

6) Are these medicines safe?
They have important risks (kidney issues, ONJ, atypical femur fractures, hypocalcemia, rebound effects). Labels must be followed; dentists and surgeons should be informed. FDA Access Data+1

7) Do children get the same medicines as adults?
Children with severe fragility may receive cyclic IV pamidronate or other regimens in OI; use in BCARD is individualized and off-label. Growth and dental considerations matter. PMC

8) How often do I need artery scans?
Depends on baseline size and growth; your vascular team sets intervals (e.g., 6–12 months for known dilation). Immediate imaging if sudden severe pain occurs. AHA Journals

9) Can I exercise?
Yes—low-impact, supervised programs improve strength and balance and can lower fracture risk. Avoid contact/high-impact sports. PMC

10) Will I lose hearing?
Sensorineural hearing loss is common; early audiology and hearing aids/cochlear implants help communication and development. NCBI

11) What about pregnancy?
Plan with high-risk obstetrics and vascular teams; monitor aorta/arteries closely due to hemodynamic stress. Delivery planning is individualized. AHA Journals

12) What surgeries are most common?
Fracture fixation, corrective limb/spine surgery, and in some, elective vascular repair when aneurysm size or growth meets criteria; cochlear implantation for severe hearing loss. AHA Journals

13) Do I need to change my diet?
Aim for enough calcium, vitamin D, and protein; limit salt; keep a healthy body weight. Supplements only as your clinician recommends. FDA Access Data

14) Should my family be tested?
Yes, relatives may be carriers. Genetic counseling discusses testing, reproductive options, and newborn/child screening where appropriate. NCBI

15) Where can I learn more?
Medical summaries at NCBI MedGen, Orphanet, GARD, Monarch provide overviews; clinicians use ACC/AHA and ESVS guidelines for aortic care, and OI literature to inform bone management. ESVS+5NCBI+5Orpha.net+5

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 30, 2025.